University of Groningen

• Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
• “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
• Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
• from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.

• Fortanix® Inc. , the data security company and pioneer of Confidential Computing, today announced new capabilities for Fortanix Data Security Manager (DSM) to help public and private organizations address growing data sovereignty requirements globally.
• Organizations around the globe are taking urgent steps to meet strict, complex, and changing data sovereignty regulations.
• “Data sovereignty goes beyond just where data resides; it is a multi-layered approach that encompasses data security, protection, and privacy.
• Fortanix will once again have a presence at it-sa Expo&Congress 2023, Europe's largest trade event for IT security.

• Despite signifying an impending crisis, such images make climate change seem abstract – happening a long way off (for most of us), to animals we’ve probably never encountered.
• The authors argue the psychological distance of climate change has been overestimated – according to their results, most people view climate change as “psychologically close”.

A review of the evidence

• To investigate how prevalent psychological distance to climate change really is – and whether it might prevent climate action – the researchers systematically reviewed the available evidence.
• In short, the evidence for the idea that psychological distance is preventing us from climate action is very mixed.
• Third, after examining 30 studies, the team found very little evidence that experiments aimed at changing people’s perception of the psychological distance of climate change actually increase their climate action.

How should we communicate about the climate, then?

• Our own Australian Psychological Society recommends reducing psychological distance by making the local impacts of climate change more salient.
• For example, highlighting the increase in the number of extreme heat days in one’s town or region.
• At worst, repeating ideas about psychological distance could lead people to overestimate the extent to which others think climate change is psychologically distant.

We already know it’s here, now let’s act

• If people know that climate change is near and now, why do we need to reinforce that idea?
• Our efforts might be better spent increasing people’s belief in being able to take climate action (“self-efficacy”), and that those actions will be effective (“response-efficacy”).

Climate change hasn’t moved ‘closer’

• There is no doubt climate change is becoming more “real” and more concerning for most of us.
• From 2018 to 2022, the number of Australians “very concerned” about climate change has nearly doubled, from 24% to 42%.
• We know climate change is affecting polar bears, but we also know it is affecting us right now.

• BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.
• Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio.
• He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner.
• His deep experience in life-science capital markets will benefit VectivBio as we enter our next stage of growth,” said Tom Woiwode, VectivBio Board Chairman.